BioCentury | May 18, 2018
Finance

China comes to Europe

...$35.0 Series D Johnson & Johnson Development Corp., BB Biotech Ventures, LSP, Novartis Venture Fund, Consort Medical plc...
BioCentury | Mar 22, 2018
Company News

Management tracks: Novo, Nabriva

...acquired. Ilett was non-executive director at Oxular Ltd. (Oxford, U.K.) and group general counsel at Consort Medical plc...
BioCentury | Jan 27, 2017
Financial News

Atlas Genetics completes venture financing

...round on Jan. 23. New investor Wondfo Biotech participated alongside existing investors Novartis Venture Funds, Consort Medical plc...
BioCentury | Jan 24, 2017
Financial News

Atlas Genetics raises $35M in series D

...a series D round. New investor Wondfo Biotech participated alongside existing investors Novartis Venture Funds, Consort Medical plc...
BioCentury | Jul 19, 2016
Financial News

Precision Ocular closes L15.5M round

...with L15.5 million ($20.5 million) led by Imperial Innovations Group plc (LSE:IVO). Other investors include Consort Medical plc...
BioCentury | Feb 2, 2015
Financial News

Atlas Genetics completes venture financing

...Date completed: 2015-01-29 Type: Venture financing Raised: $20 million Investors: RMI Partners; Novartis Venture Funds; Consort Medical plc...
BioCentury | Jan 30, 2015
Financial News

Atlas Genetics raises $20M in series C round

...from new investor RMI Partners, a subsidiary of Rusnano, and existing investors Novartis Venture Funds; Consort Medical plc...
BioCentury | Dec 8, 2014
Company News

Aesica Pharmaceuticals, Consort Medical deal

...develops and manufactures disposable drug delivery devices. Aesica Pharmaceuticals Ltd. , Newcastle upon Tyne, U.K. Consort Medical plc...
BioCentury | May 5, 2014
Financial News

Atlas Genetics financial update

...series B round, bringing the total raised to £16.9 million ($28.5 million). Novartis Venture Funds; Consort Medical...
BioCentury | Oct 14, 2013
Company News

Ablynx antibodies news

...7% stake. Nanobodies are therapeutic proteins based on single-domain antibody fragments. Fellner is chairman of Consort Medical plc...
Items per page:
1 - 10 of 18
BioCentury | May 18, 2018
Finance

China comes to Europe

...$35.0 Series D Johnson & Johnson Development Corp., BB Biotech Ventures, LSP, Novartis Venture Fund, Consort Medical plc...
BioCentury | Mar 22, 2018
Company News

Management tracks: Novo, Nabriva

...acquired. Ilett was non-executive director at Oxular Ltd. (Oxford, U.K.) and group general counsel at Consort Medical plc...
BioCentury | Jan 27, 2017
Financial News

Atlas Genetics completes venture financing

...round on Jan. 23. New investor Wondfo Biotech participated alongside existing investors Novartis Venture Funds, Consort Medical plc...
BioCentury | Jan 24, 2017
Financial News

Atlas Genetics raises $35M in series D

...a series D round. New investor Wondfo Biotech participated alongside existing investors Novartis Venture Funds, Consort Medical plc...
BioCentury | Jul 19, 2016
Financial News

Precision Ocular closes L15.5M round

...with L15.5 million ($20.5 million) led by Imperial Innovations Group plc (LSE:IVO). Other investors include Consort Medical plc...
BioCentury | Feb 2, 2015
Financial News

Atlas Genetics completes venture financing

...Date completed: 2015-01-29 Type: Venture financing Raised: $20 million Investors: RMI Partners; Novartis Venture Funds; Consort Medical plc...
BioCentury | Jan 30, 2015
Financial News

Atlas Genetics raises $20M in series C round

...from new investor RMI Partners, a subsidiary of Rusnano, and existing investors Novartis Venture Funds; Consort Medical plc...
BioCentury | Dec 8, 2014
Company News

Aesica Pharmaceuticals, Consort Medical deal

...develops and manufactures disposable drug delivery devices. Aesica Pharmaceuticals Ltd. , Newcastle upon Tyne, U.K. Consort Medical plc...
BioCentury | May 5, 2014
Financial News

Atlas Genetics financial update

...series B round, bringing the total raised to £16.9 million ($28.5 million). Novartis Venture Funds; Consort Medical...
BioCentury | Oct 14, 2013
Company News

Ablynx antibodies news

...7% stake. Nanobodies are therapeutic proteins based on single-domain antibody fragments. Fellner is chairman of Consort Medical plc...
Items per page:
1 - 10 of 18